Physician profile
Hiroto Inaba
NPI 1356533046
$67,110.58
in general payments reported to CMS, 2019-2025
10 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,040 · 2021: $17K · 2022: $6,353 · 2023: $7,608 · 2024: $7,396 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $1,023 · Travel and Lodging: $18.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,604.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,095.84 |
| Food and Beverage | $1,022.62 |
| Travel and Lodging | $18.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30,918.34 | 2021-2025 | Blincyto |
| Jazz Pharmaceuticals INC. | $25,467.56 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $6,410.00 | 2020-2024 | |
| Syndax Pharmaceuticals, INC. | $2,114.68 | 2025 | Revuforj |
| Chugai Pharmaceutical Co., LTD. | $1,320.00 | 2021 | |
| Sumitomo Pharma Co., LTD. | $880.00 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiroto Inaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.